| COVID-19 Clinical Research Studies | Lifetime | 210 | GB 21 | 98.97 |
| Blood Pressure and Hypertension Studies | Lifetime | 141 | GB 12 | 99.47 |
| Heart Failure Treatment and Management | Lifetime | 110 | GB 8 | 99.57 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 282 | GB 50 | 99.15 |
| Cardiovascular Function and Risk Factors | Lifetime | 311 | GB 19 | 99.40 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 254 | GB 10 | 99.32 |
| Clinical practice guidelines implementation | Lifetime | 91 | GB 20 | 98.64 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 140 | GB 16 | 98.42 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 42 | GB 13 | 98.78 |
| Primary Care and Health Outcomes | Lifetime | 158 | GB 30 | 98.85 |
| Cardiac pacing and defibrillation studies | Lifetime | 269 | GB 13 | 99.11 |
| Healthcare Systems and Technology | Lifetime | 80 | GB 22 | 98.33 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 878 | GB 66 | 97.31 |
| Lipoproteins and Cardiovascular Health | Lifetime | 478 | GB 49 | 98.05 |
| Medication Adherence and Compliance | Lifetime | 164 | GB 11 | 97.29 |
| COVID-19 and healthcare impacts | Lifetime | 484 | GB 81 | 94.61 |
| Chronic Disease Management Strategies | Lifetime | 552 | GB 115 | 96.76 |
| Cardiac Health and Mental Health | Lifetime | 579 | GB 48 | 96.39 |
| Healthcare professionals’ stress and burnout | Lifetime | 466 | GB 43 | 95.27 |
| Workplace Violence and Bullying | Lifetime | 171 | GB 20 | 94.47 |
| Healthcare cost, quality, practices | Lifetime | 673 | GB 99 | 92.82 |
| Medical Coding and Health Information | Lifetime | 229 | GB 33 | 86.64 |
| Potassium and Related Disorders | Lifetime | 723 | GB 44 | 88.13 |
| Sodium Intake and Health | Lifetime | 935 | GB 58 | 88.35 |
| Clinical Laboratory Practices and Quality Control | Lifetime | 767 | GB 66 | 81.91 |
| French Literature and Poetry | Lifetime | 359 | GB 56 | 75.67 |
| Otolaryngology and Infectious Diseases | Lifetime | 922 | GB 72 | 76.56 |
| COVID-19 Clinical Research Studies | 2021-2025 | 179 | GB 20 | 99.03 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 499 | GB 44 | 97.95 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 122 | GB 9 | 97.51 |
| Heart Failure Treatment and Management | 2021-2025 | 323 | GB 29 | 96.05 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 950 | GB 136 | 93.17 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 989 | GB 67 | 94.02 |
| Cardiac Health and Mental Health | 2021-2025 | 976 | GB 69 | 80.69 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 404 | GB 37 | 70.90 |
